• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.基于质谱流式细胞术的肝移植患者不同免疫表型对肿瘤复发的预测
Am J Cancer Res. 2022 Sep 15;12(9):4160-4176. eCollection 2022.
2
Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.同型半胱氨酸:甲胎蛋白阴性肝细胞癌肝移植的新型预后生物标志物。
Cancer Biomark. 2020;29(2):197-206. doi: 10.3233/CBM-201545.
3
Prophylactic liver transplantation for high-risk recurrent hepatocellular carcinoma.高危复发性肝细胞癌的预防性肝移植
World J Hepatol. 2016 Nov 8;8(31):1309-1317. doi: 10.4254/wjh.v8.i31.1309.
4
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.验证一种用于肝移植后肝细胞癌复发的肿瘤复发风险评估(RETREAT)评分。
JAMA Oncol. 2017 Apr 1;3(4):493-500. doi: 10.1001/jamaoncol.2016.5116.
5
R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation.R3-AFP评分是一种新的综合工具,用于优化肝移植后肝细胞癌复发的预测。
JHEP Rep. 2022 Feb 2;4(5):100445. doi: 10.1016/j.jhepr.2022.100445. eCollection 2022 May.
6
Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy.接受移植前直接抗病毒(DAA)治疗的丙型肝炎病毒(HCV)肝移植受者肝细胞癌的复发情况
Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14.
7
Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.米兰标准内肝细胞癌患者肝移植前桥接局部区域治疗的影响:来自美国多中心肝癌移植联盟的3601例患者分析
Ann Surg. 2017 Sep;266(3):525-535. doi: 10.1097/SLA.0000000000002381.
8
High expression of protein phosphatase 2 regulatory subunit B'' alpha predicts poor outcome in hepatocellular carcinoma patients after liver transplantation.蛋白磷酸酶2调节亚基B''α的高表达预示着肝细胞癌患者肝移植后的不良预后。
World J Gastrointest Oncol. 2021 Jul 15;13(7):716-731. doi: 10.4251/wjgo.v13.i7.716.
9
A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.一种新型预后列线图可准确预测肝移植后肝细胞癌复发:对865例连续肝移植受者的分析
J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.
10
Assessing Competing Risks for Death Following Liver Transplantation for Hepatocellular Carcinoma.评估肝癌患者肝移植术后死亡的竞争风险。
Dig Dis Sci. 2019 Apr;64(4):1001-1007. doi: 10.1007/s10620-019-05538-1.

引用本文的文献

1
State-of-the-art cytometry in the search of novel biomarkers in digestive cancers.在消化系统癌症中寻找新型生物标志物的前沿流式细胞术
Front Oncol. 2024 May 29;14:1407580. doi: 10.3389/fonc.2024.1407580. eCollection 2024.
2
Dynamic immune recovery process after liver transplantation revealed by single-cell multi-omics analysis.单细胞多组学分析揭示肝移植后的动态免疫恢复过程
Innovation (Camb). 2024 Mar 1;5(3):100599. doi: 10.1016/j.xinn.2024.100599. eCollection 2024 May 6.
3
Application of Mass Cytometry Platforms to Solid Organ Transplantation.应用液质联用平台进行实体器官移植。
Transplantation. 2024 Oct 1;108(10):2034-2044. doi: 10.1097/TP.0000000000004925. Epub 2024 Mar 12.
4
γδ T Cells: A Game Changer in the Future of Hepatocellular Carcinoma Immunotherapy.γδ T 细胞:在肝细胞癌免疫治疗的未来中具有变革意义。
Int J Mol Sci. 2024 Jan 23;25(3):1381. doi: 10.3390/ijms25031381.
5
Therapeutic Approach to Post-Transplant Recurrence of Hepatocellular Carcinoma: Certainties and Open Issues.肝细胞癌移植后复发的治疗方法:确定因素与未决问题
Cancers (Basel). 2023 Nov 26;15(23):5593. doi: 10.3390/cancers15235593.
6
Circulating the HLA-DR+ T Cell Ratio Is a Prognostic Factor for Recurrence of Patients with Hepatocellular Carcinoma after Curative Surgery.循环HLA-DR+ T细胞比例是肝细胞癌根治性切除术后患者复发的一个预后因素。
J Oncol. 2023 Feb 23;2023:1875153. doi: 10.1155/2023/1875153. eCollection 2023.

本文引用的文献

1
Adaptation of Imaging Mass Cytometry to Explore the Single Cell Alloimmune Landscape of Liver Transplant Rejection.将成像质谱细胞术用于探索肝移植排斥的单细胞同种异体免疫景观的适应性研究。
Front Immunol. 2022 Mar 31;13:831103. doi: 10.3389/fimmu.2022.831103. eCollection 2022.
2
Harnessing Mechanisms of Immune Tolerance to Improve Outcomes in Solid Organ Transplantation: A Review.利用免疫耐受机制改善实体器官移植的结局:综述。
Front Immunol. 2021 Jun 10;12:688460. doi: 10.3389/fimmu.2021.688460. eCollection 2021.
3
Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.治疗方式对肝移植后复发性肝细胞癌患者的影响:初步经验。
Hepatobiliary Pancreat Dis Int. 2020 Aug;19(4):365-370. doi: 10.1016/j.hbpd.2020.06.002. Epub 2020 Jun 7.
4
Liver transplantation for hepatocellular carcinoma: Management after the transplant.肝移植治疗肝细胞癌:移植后的管理。
Am J Transplant. 2020 Feb;20(2):333-347. doi: 10.1111/ajt.15697. Epub 2019 Dec 9.
5
Distinct phenotype of CD4 T cells driving celiac disease identified in multiple autoimmune conditions.在多种自身免疫性疾病中鉴定出驱动乳糜泻的 CD4 T 细胞的独特表型。
Nat Med. 2019 May;25(5):734-737. doi: 10.1038/s41591-019-0403-9. Epub 2019 Mar 25.
6
Myeloid-derived suppressor cells in transplantation: the dawn of cell therapy.移植中的髓源性抑制细胞:细胞治疗的曙光。
J Transl Med. 2018 Jan 29;16(1):19. doi: 10.1186/s12967-018-1395-9.
7
The pretransplant neutrophil-lymphocyte ratio as a new prognostic predictor after liver transplantation for hepatocellular cancer: a systematic review and meta-analysis.移植前中性粒细胞与淋巴细胞比值作为肝癌肝移植后新的预后预测因子:系统评价和荟萃分析。
Biomark Med. 2018 Feb;12(2):189-199. doi: 10.2217/bmm-2017-0307. Epub 2018 Jan 12.
8
Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches.肝移植治疗肝细胞癌:结果与新型手术方法。
Nat Rev Gastroenterol Hepatol. 2017 Apr;14(4):203-217. doi: 10.1038/nrgastro.2016.193. Epub 2017 Jan 5.
9
Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.验证一种用于肝移植后肝细胞癌复发的肿瘤复发风险评估(RETREAT)评分。
JAMA Oncol. 2017 Apr 1;3(4):493-500. doi: 10.1001/jamaoncol.2016.5116.
10
Mass cytometry reveals a distinct immunoprofile of operational tolerance in pediatric liver transplantation.质谱流式细胞术揭示了小儿肝移植中操作性耐受的独特免疫特征。
Pediatr Transplant. 2016 Dec;20(8):1072-1080. doi: 10.1111/petr.12795. Epub 2016 Oct 26.

基于质谱流式细胞术的肝移植患者不同免疫表型对肿瘤复发的预测

Prediction of tumor recurrence by distinct immunoprofiles in liver transplant patients based on mass cytometry.

作者信息

Wei Xuyong, Xie Wentao, Yin Weiwei, Yang Mengfan, Khan Abdul Rehman, Su Renyi, Shu Wenzhi, Pan Binhua, Fan Guanghan, Wang Kun, Yang Fan, Lu Di, Li Changbiao, Pan Linhui, Cen Beini, Xie Haiyang, Zhuang Li, Zheng Shusen, Zeng Xun, Chen Wei, Xu Xiao

机构信息

Department of Hepatobiliary and Pancreatic Surgery, Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine Hangzhou 310006, China.

NHFPC Key Laboratory of Combined Multi-Organ Transplantation Hangzhou 310003, China.

出版信息

Am J Cancer Res. 2022 Sep 15;12(9):4160-4176. eCollection 2022.

PMID:36225628
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9548010/
Abstract

Recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) is a marker of poor prognosis. However, the reliable biomarkers of post-LT HCC recurrence remain to be identified. In this study, serial peripheral blood samples from the LT recipients with and without HCC recurrence were collected at five time points. Single-cell mass cytomertry (CyTOF) was utilized for the in-depth analysis of peripheral blood monocellular cells (PBMCs). CyTOF analysis showed that at 3 weeks post-LT, the activated immune cell population was increased, while the fraction of immune cells with suppressive functions (myeloid-derived suppressive cells) was reduced. The post-LT immune composition in patients with LT for HCC was enormously different from that in patients with LT for causes other than HCC. Furthermore, at 3 weeks after LT, compared with patients without recurrence, the patients with HCC recurrences were high in two subsets of T cells: CD57 HLA-DR CD8 and CD28γδ. The CD57 HLA-DR CD8 T cells presented high levels of perforin, granzyme B, and Ki-67 and displayed a highly cytotoxic and proliferative phenotype, while the CD28γδ T cells had reduced levels of IFN-γ and, hence, were less activated compared to CD28 cells. Based on these findings, we concluded that analyzing the PBMCs of LT recipients by CyTOF can predict the post-LT HCC recurrence. The distinct immune features can stratify patients with the risk of HCC recurrence at 3 weeks after LT, which will help clinician in further management plan and improve the prognosis of patients.

摘要

肝移植(LT)后肝细胞癌(HCC)复发是预后不良的一个标志。然而,LT后HCC复发的可靠生物标志物仍有待确定。在本研究中,在五个时间点收集了有或无HCC复发的LT受者的系列外周血样本。利用单细胞质谱流式细胞术(CyTOF)对外周血单个核细胞(PBMC)进行深入分析。CyTOF分析显示,LT后3周,活化的免疫细胞群体增加,而具有抑制功能的免疫细胞(髓系来源的抑制细胞)比例降低。HCC患者LT后的免疫组成与非HCC原因导致LT的患者有很大不同。此外,LT后3周,与未复发的患者相比,HCC复发患者的两个T细胞亚群水平较高:CD57 HLA-DR CD8和CD28γδ。CD57 HLA-DR CD8 T细胞表现出高水平的穿孔素、颗粒酶B和Ki-67,并表现出高度细胞毒性和增殖表型,而CD28γδ T细胞的IFN-γ水平降低,因此与CD28细胞相比活化程度较低。基于这些发现,我们得出结论,通过CyTOF分析LT受者的PBMC可以预测LT后HCC复发。这些独特的免疫特征可以在LT后3周对有HCC复发风险的患者进行分层排序,这将有助于临床医生制定进一步的管理计划并改善患者的预后。